Moderna (MRNA, $180.89) and Pfizer(PFE, $53.28) get FDA approval on second booster shot
Moderna and Pfizer shares climbed, after the U.S. Food & Drug Administration authorized the use of a second shot of Covid boosters developed by the pharma companies.
According to the FDA, adults over the age of 50, as well as those with compromised immune systems, can receive a booster dose of either the Pfizer or Moderna vaccine at least four months after receiving the first.
Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, mentioned that current evidence suggests some waning of protection over time against serious outcomes from COVID-19 in older and immunocompromised individuals. Marks said that a second booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine could help increase protection levels for these higher-risk individuals. He also said that data revealed that an initial booster dose is critical in boosting protection for all adults from the potentially severe outcomes of COVID-19. “So, those who have not received their initial booster dose are strongly encouraged to do so,”Marks added.
MRNA sees MACD Histogram just turned negative
MRNA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on March 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MRNA moved out of overbought territory on March 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where MRNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRNA broke above its upper Bollinger Band on February 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on February 17, 2026. You may want to consider a long position or call options on MRNA as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 168 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.438) is normal, around the industry mean (30.264). P/E Ratio (0.000) is within average values for comparable stocks, (40.876). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.802). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (10.811) is also within normal values, averaging (313.223).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement